Yuan Alex, Kaiser Peter K
Cole Eye Institute, Cleveland, OH 44195, USA.
Semin Ophthalmol. 2011 May;26(3):149-55. doi: 10.3109/08820538.2011.570846.
Numerous drugs that show promise in the treatment of neovascular age related macular degeneration are currently being evaluated in early clinical trials. Some of these drugs target the vascular endothelial growth factor pathway while others act on different targets along the angiogenesis cascade. The mechanism of action of these novel therapeutics and the results of early clinical trials will be discussed along with a review of angiogenesis.
目前，许多有望用于治疗新生血管性年龄相关性黄斑变性的药物正在早期临床试验中进行评估。其中一些药物靶向血管内皮生长因子通路，而其他药物则作用于血管生成级联反应中的不同靶点。本文将讨论这些新型疗法的作用机制以及早期临床试验的结果，并对血管生成进行综述。
